Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963659 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL4804191 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL22335649 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL24063582 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL13495796 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL24772408 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL23969062 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL23990344 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL22236573 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO | |
| SCHEMBL10148608 | 1.00 | MEN1 (0.70) | MEN1KMT2ALMNACYP1A2THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | OPKO PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | MEN1 3918/4885KMT2A 4002/4885LMNA 4846/4885 |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | SI, GYS1, UGGT1 | MEN1 3918/4885KMT2A 4002/4885LMNA 4846/4885 |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | MEN1 3918/4885KMT2A 4002/4885LMNA 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.